Assisi Alessandro, Banzi Rita, Buonocore Carmela, Capasso Filippo, Di Muzio Valeria, Michelacci Francesca, Renzo Danila, Tafuri Giovanni, Trotta Francesco, Vitocolonna Maria, Garattini Silvio
Regulatory Policies Laboratory, Mario Negri Institute for Pharmacological Research, Milan, Italy.
Int Clin Psychopharmacol. 2006 Nov;21(6):319-36. doi: 10.1097/01.yic.0000224790.98534.11.
Epidemiological and experimental studies have indicated that consumption of more n-3 long-chain polyunsaturated fatty acids may reduce the risk for a variety of diseases, including cardiovascular, neurological and immunological disorders, diabetes and cancer. This article focuses on the role of marine n-3 long-chain polyunsaturated fatty acids in brain functions, including the development of the central nervous system and neurological disorders. An overview of the major animal studies and clinical trials is provided here, focusing on fatty acid supplementation during pregnancy and infancy, and prevention and management of Alzheimer's disease, schizophrenia, depression and attention deficit hyperactive disorder. Although an optimal balance in n-3/n-6 long-chain polyunsaturated fatty acid ratio is important for proper neurodevelopment and cognitive functions, results from randomized controlled trials are controversial and do not confirm any useful effect of supplementation on development of preterm and term infants. The relationship between fatty acid status and mental disorders is confirmed by reduced levels of n-3 long-chain polyunsaturated fatty acids in erythrocyte membranes of patients with central nervous system disorders. Nevertheless, there are very little data supporting the use of fish oil in those patients. The only way to verify whether n-3 long-chain polyunsaturated fatty acids are a potential therapeutic option in the management and prevention of mental disorders is to conduct a large definitive randomized controlled trials similar to those required for the licensing of any new pharmacological treatment.
流行病学和实验研究表明,摄入更多的n-3长链多不饱和脂肪酸可能会降低患多种疾病的风险,包括心血管疾病、神经和免疫紊乱、糖尿病和癌症。本文重点关注海洋n-3长链多不饱和脂肪酸在脑功能中的作用,包括中枢神经系统的发育和神经紊乱。本文提供了主要动物研究和临床试验的概述,重点关注孕期和婴儿期的脂肪酸补充,以及阿尔茨海默病、精神分裂症、抑郁症和注意力缺陷多动障碍的预防和管理。虽然n-3/n-6长链多不饱和脂肪酸比例的最佳平衡对正常的神经发育和认知功能很重要,但随机对照试验的结果存在争议,并未证实补充剂对早产和足月婴儿发育有任何有益效果。中枢神经系统疾病患者红细胞膜中n-3长链多不饱和脂肪酸水平降低,证实了脂肪酸状态与精神障碍之间的关系。然而,几乎没有数据支持在这些患者中使用鱼油。验证n-3长链多不饱和脂肪酸是否是管理和预防精神障碍的潜在治疗选择的唯一方法,是进行一项大型确定性随机对照试验,类似于任何新药理学治疗许可所需的试验。